Hydrogen Peroxide and Ultraviolet Light for Disinfecting Surfaces in Intensive Care Units: A Randomized, Controlled, Cluster, Crossover Clinical Trial

Healthcare-associated infections (HAIs) remain a major problem in intensive care units (ICUs), driven by environmental contamination with multidrug-resistant organisms that persist despite routine manual cleaning. While hydrogen peroxide aerosolization and ultraviolet-C light devices have shown promise in reducing surface contamination, current evidence is inconsistent, mostly derived from single-center studies, and rarely linked to patient-centered outcomes.
The investigators will conduct this cluster-randomized, crossover trial in 12 Brazilian ICUs. Each ICU will sequentially implement three strategies: (1) usual surface disinfection; (2) usual surface disinfection followed by hydrogen peroxide aerosolization at 7.9% concentration, applied through a dedicated device inside a protective tent during terminal cleaning of patient beds; and (3) usual surface disinfection followed by automated ultraviolet-C irradiation, also applied under the same tent to shield adjacent occupied beds.
The primary outcome will be the average duration of antimicrobial therapy, with secondary outcomes including HAI incidence, environmental contamination with multidrug-resistant organisms, specific HAIs (associated-ventilator pneumonia, central-line associated bloodstream infection, and catheter-associated urinary tract infection), and ICU length of stay costs.

Start Date05 Jan 2026

Sponsor / Collaborator

Hospital Israelita Albert Einstein

[+2]

CTRI/2025/12/099303

/ Not yet recruitingPhase 2/3IIT

Clinical Efficacy of 17% Hydrogen Peroxide alone or in Combination with Cobalt-Tetraphenylporphyrin Complex, Functionalized with Reduced Graphene Oxide for Bleaching in Adults with Moderate Fluorosis - NIL

Start Date01 Jan 2026

Sponsor / Collaborator-

ChiCTR2500113262

/ Not yet recruitingEarly Phase 1IIT

A Randomized Parallel, Controlled, Evaluator-Blinded Clinical Study on the Treatment of Viral Warts with Warm Therapy Combined with Hydrogen Peroxide (H2O2) Microneedle Patches

Start Date01 Dec 2025

Sponsor / Collaborator

The First Hospital Of China Medical University

100 Clinical Results associated with Hydrogen Peroxide

100 Translational Medicine associated with Hydrogen Peroxide

100 Patents (Medical) associated with Hydrogen Peroxide

171,889

Literatures (Medical) associated with Hydrogen Peroxide

01 Jun 2026·Food chemistry. Molecular sciences

Effects of hot water treatment, silver hydroxide ion solution and carboxymethyl chitosan on Lanxangia tsao-ko quality

Article

Author: Yang, Weize ; Yang, Tianmei ; Yang, Meiquan ; Zhang, Jinyu ; Zeng, Anqiong

The fruit of Lanxangia tsao - ko (LT), a widely used spice, is highly perishable during storage and transportation making it essential to develop effective preservation methods. This study employed multi-omics techniques to evaluate the effects of three different treatments on the quality of LT during short-term storage. Results demonstrated that, compared to the tap water control group (TW), the hot water treatment group (HW), carboxymethyl chitosan treatment group (CMC), and hydrogen peroxide‑silver ion solution treatment group (SP) significantly suppressed the increase in color change intensity (ΔE), browning index (BI), weight loss rate (W%), and rot rate (R%) of LT. Furthermore, these treatments promoted the accumulation of beneficial flavor substances, while reducing the level of unfavorable ones. Both CMC and SP were effective in inhibiting the increase of LT's respiration intensity and the relative abundance of pathogenic microorganisms like Rhizopus microsporus and Rhizopus arrhizus. However, HW led to an abnormal decrease in respiration intensity and increases the relative abundance of certain pathogenic microorganisms. In summary, although the temperature setting in the hot water treatment group was not ideal, hot water treatment still significantly inhibited the spoilage and discoloration phenomenon. Both CMC and SP can effectively extend the storage and transportation period of LT in all aspects. This study provides a new idea for the preservation of LT.

01 Jun 2026·FOOD MICROBIOLOGY

The effects and physiological phenotypic changes in Escherichia coli O157:H7 induced into VBNC state by hydrogen peroxide silver ion treatment in biofilms

Article

Author: Cui, Haoran ; Kong, Yajing ; Zhang, Ziyi ; Ma, Tianzhen ; Zhao, Kangning ; Duan, Menghua ; Li, Can ; Zhang, Shaochuang ; Yang, Hui ; Zeng, Shuhao ; Shi, Chao ; Wang, Xiaoya ; Ji, Runhua

Hydrogen peroxide and silver ions (HPS) is an emerging disinfectant widely used for sanitizing food contact surfaces and equipment. Escherichia coli O157:H7 is a major foodborne pathogen that represents a significant threat to public health. This study systematically evaluated the impact of growth medium (LB broth and beef broth, a food model) and temperature (25 °C and 37 °C) on the HPS-induced formation of the viable but non-culturable (VBNC) state in E. coli O157:H7 biofilms. The results indicated that, upon complete entry into the VBNC state following treatment with the same concentrations of HPS (1:40 and 1:80 dilutions), the biofilms cultured in beef broth formed the fewest VBNC state cells, at 9.26 ± 3.27 % and 13.36 ± 1.73 %, respectively, while those cultured at 37 °C formed the most VBNC state cells, at 22.60 ± 2.39 % and 23.81 ± 1.87 %, respectively. Compared to untreated cells, VBNC state cells exhibited elevated reactive oxygen species (ROS) levels, increased activities of superoxide dismutase (SOD) and catalase (CAT), reduced intracellular ATP concentrations, and depolarized membrane potentials, indicating oxidative stress and diminished metabolic activity. Morphologically, VBNC cells showed shrinkage, rough and unevenly wrinkled surfaces, and reduced cell volumes relative to untreated cells. Resuscitation of VBNC state cells was achieved within 24 h upon incubation in LB broth, LB broth supplemented with 2.0 mg/mL pyruvate, or beef broth. These findings underscore food safety risks from HPS-induced VBNC E. coli O157:H7 in biofilms, offering insights for safe HPS application in the food industry.

01 Mar 2026·FOOD MICROBIOLOGY

Effect of surfactants on the antimicrobial activity of hydrogen peroxide and chlorine dioxide foams against Listeria monocytogenes on stainless steel

Author: Ryu, Jee-Hoon ; Beuchat, Larry R. ; Yoon, Seoyoung ; Kim, Nahyun ; Kim, Hoikyung

This study evaluated the antilisterial activity of hydrogen peroxide (H₂O₂) and chlorine dioxide (ClO₂) in foam formulations containing various surfactants against Listeria monocytogenes on stainless steel coupons (SSCs). First, the minimum inhibitory and lethal concentrations of six surfactants (sodium dodecyl sulfate [SDS], cetylpyridinium chloride [CPC], cetyltrimethylammonium bromide [CTAB], coco betaine, Triton X-100, and Tween 80) were determined using planktonic cells, with CPC and CTAB exhibiting the highest activity. Second, surfactant solutions (100 μg/mL) were applied to L. monocytogenes attached to SSCs to assess surface-associated antimicrobial effects. CPC and CTAB again showed the greatest reductions, by 2.4 and 2.7 log CFU/coupon, respectively. Third, H₂O₂ (3 %) and ClO₂ (200 μg/mL) were tested alone or in combination with surfactant foams against the attached cells on SSCs. H₂O₂+CPC and H₂O₂+CTAB foams yielded the highest reductions (2.4 and 2.1 log CFU/coupon, respectively), demonstrating enhanced reductions by combination treatments compared with individual treatments. ClO₂+CPC and ClO₂+SDS foams resulted in 2.6 and 2.2 log reductions, respectively, with greater effects observed than for the individual treatments. In contrast, combinations with coco betaine, Triton X-100, or Tween 80 were less effective than H₂O₂ or ClO₂ alone. Finally, the selected foams were evaluated against L. monocytogenes biofilms formed on SSC. These findings demonstrate that the antimicrobial efficacy of H₂O₂ and ClO₂ foams can be significantly enhanced through appropriate surfactant selection, particularly against planktonic and surface-attached L. monocytogenes, while also highlighting the need for improved strategies to control biofilm-associated cells.

114

News (Medical) associated with Hydrogen Peroxide

20 Jan 2026

·www.globenewswire.com

TOMI Environmental Solutions Secures UK CES contract integrating SteraMist iHP into Total Clean Air's Modular Cleanroom Platform

FREDERICK, Md., Jan. 20, 2026 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global leader in disinfection and decontamination solutions, today announced the sale of a Custom Engineered System (CES) in the United Kingdom to an international pharmaceutical manufacturing organization. The system is being delivered as part of a bespoke, modular cleanroom platform designed, engineered, and validated by Total Clean Air Limited (“TCA”), one of the United Kingdom’s leading authorities in GMP, EMA, and UK regulatory-compliant clean air and containment solutions. SteraMist iHP has been fully integrated into TCA’s modular cleanroom architecture, marking the first deployment of iHP technology within TCA’s modular platform. This integration establishes a repeatable, scalable, and regulator-ready model for future pharmaceutical cleanroom developments across the UK and wider international markets. TCA’s modular solution has been developed to align with UK MHRA and EMA expectations, embedding decontamination capability directly into the cleanroom lifecycle — from design and construction through qualification, validation, and ongoing operation. This approach ensures pharmaceutical operators benefit from assured compliance, operational resilience, and long-term facility performance, rather than bolt-on or post-handover solutions. This project further reinforces TCA’s position as a trusted cleanroom delivery partner to pharmaceutical manufacturers, providing fully integrated solutions spanning cleanroom design, controlled environments, containment, HVAC, validation, and clean air strategy. Phillip Godden, Chief Executive Officer of Total Clean Air, commented: “At Total Clean Air, our role is to engineer certainty into pharmaceutical environments. Integrating SteraMist iHP directly into our modular cleanroom platform allows us to deliver a fully aligned, regulator-ready decontamination strategy that supports both UK and EMA expectations from day one. This collaboration demonstrates how advanced decontamination technology, when properly embedded into cleanroom design and validation, enhances patient safety, operational confidence, and long-term compliance. We see this as a strong foundation for continued collaboration in the UK and internationally.” Elissa (E.J.) Shane, Chief Operating Officer of TOMI Environmental Solutions, added: “This CES deployment represents an important step in TOMI’s international growth strategy. Partnering with Total Clean Air enables SteraMist iHP to be embedded within a robust, high-quality modular cleanroom platform that is already aligned with stringent pharmaceutical regulatory frameworks. By working with a specialist such as Total Clean Air, we are creating a scalable pathway for future system deployments while supporting pharmaceutical manufacturers with integrated, compliant decontamination solutions.” The collaboration reflects a shared commitment to engineering-led design, regulatory integrity, and patient-focused outcomes, positioning both organizations to support the continued expansion of high-quality pharmaceutical manufacturing capacity in the UK and beyond. About TOMI™ Environmental Solutions, Inc.: Innovating for a safer world® TOMI™ Environmental Solutions, Inc. (NASDAQ:TOMZ) is a global decontamination and infection prevention company, providing environmental solutions for indoor surface disinfection through the manufacturing, sales and licensing of its premier Binary Ionization Technology® (BIT™) platform. Invented under a defense grant in association with the Defense Advanced Research Projects Agency (DARPA) of the U.S. Department of Defense, BIT™ solution utilizes a low percentage Hydrogen Peroxide as its only active ingredient to produce a fog of ionized Hydrogen Peroxide (iHP™). Represented by the SteraMist® brand of products, iHP™ produces a germ-killing aerosol that works like a visual non-caustic gas. TOMI products are designed to service a broad spectrum of commercial structures, including, but not limited to, hospitals and medical facilities, cruise ships, office buildings, hotel and motel rooms, schools, restaurants, meat and produce processing facilities, military barracks, police and fire departments, and athletic facilities. TOMI products and services have also been used in single-family homes and multi-unit residences. TOMI develops training programs and application protocols for its clients and is a member in good standing with The American Biological Safety Association, The American Association of Tissue Banks, Association for Professionals in Infection Control and Epidemiology, Society for Healthcare Epidemiology of America, America Seed Trade Association, and The Restoration Industry Association. For additional information, please visit https://www.steramist.com or contact us at info@tomimist.com. About Total Clean Air LimitedTotal Clean Air Limited is a UK-based clean air and controlled environments specialist, delivering design, build, validation, and lifecycle support for cleanrooms, containment laboratories, and critical ventilation systems. Operating across pharmaceutical, life sciences, healthcare, and advanced manufacturing sectors, Total Clean Air is recognised for its engineering-led approach, UKAS-accredited validation capability, and strong ‘We Care’ culture underpinning long-term client partnerships. Forward-Looking Statements This press release contains forward-looking statements that are based on current expectations, estimates, forecasts and projections of future performance based on management’s judgment, beliefs, current trends, and anticipated product performance. These forward-looking statements include, without limitation, statements regarding expansion of UK and international markets and ability to achieve revenue growth. Forward-looking statements involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. These factors include, but are not limited to, our ability to acquire new customers and expands sales; our ability to maintain and manage growth and generate sales, our reliance on a single or a few products for a majority of revenues; the general business and economic conditions; and other risks as described in our SEC filings, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 filed by us with the SEC and other periodic reports we filed with the SEC. The information provided in this document is based upon the facts and circumstances known at this time. Other unknown or unpredictable factors or underlying assumptions subsequently proving to be incorrect could cause actual results to differ materially from those in the forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance, or achievements. You should not place undue reliance on these forward-looking statements. All information provided in this press release is as of today’s date, unless otherwise stated, and we undertake no duty to update such information, except as required under applicable law. INVESTOR RELATIONS CONTACT: John Nesbett/Rosalyn Christian IMS Investor Relations tomi@imsinvestorrelations.com

18 Dec 2025

·www.globenewswire.com

TOMI Environmental Solutions Secures a Purchase Order of Approximately $500,000 for the Integration of SteraMist iHP Technology within a Global Biopharmaceutical Leader

FREDERICK, Md., Dec. 18, 2025 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global leader in disinfection and decontamination solutions, announced today announced it has received a significant signed purchase contract including a purchase order valued at approximately $500,000 from one of the world's largest and most respected biopharmaceutical companies. This order is for the complete integration of TOMI's SteraMist Integrated Systems (SIS) platform into critical manufacturing infrastructure. The purchase contract specifically mandates the use of SteraMist iHP technology into passthrough fill boxes—a crucial component in the client's sterile manufacturing and advanced therapeutic production process. These systems will be deployed across two separate areas in the global biopharma company specializing in the discovery, development, and manufacture of innovative medicines. The SteraMist Integrated Systems (SIS) will provide a fully automated, rapid, and residue-free decontamination solution for both critical chambers. The scope of this contract also includes comprehensive installation and performance qualification (PQ) services delivered by TOMI’s expert technical team, ensuring the systems meet stringent biopharmaceutical regulatory requirements for validation. The SIS platform, formally launched in late 2024, is designed to meet the escalating industry demand for automated, in-line, and high-throughput decontamination. These two projects were previously discussed as part of the $13 million pipeline for automated installation projects, underscoring the SIS platform's effectiveness as it actively drives the pipeline. While the current order focuses on two locations, the increasing industry interest is demonstrated by the robust pipeline of orders anticipated throughout 2026 and beyond. Elissa (E.J.) Shane, TOMI’s Chief Operating Officer, commented on the milestone: “We value the opportunity to work closely with large pharmaceutical organizations to support their critical manufacturing and sterility assurance needs. We are seeing increasing recognition among large pharmaceutical and biopharmaceutical organizations of the efficacy, material compatibility, and automation advantages of SteraMist iHP technology. In particular, the SteraMist Integrated System platform is generating exceptionally promising interest. As companies evaluate solutions that meet rigorous validation and throughput requirements, the SteraMist Integrated System directly addresses the demand for advanced automation in laboratory and manufacturing chambers.” About TOMI™ Environmental Solutions, Inc.: Innovating for a safer world® TOMI™ Environmental Solutions, Inc. (NASDAQ:TOMZ) is a global decontamination and infection prevention company, providing environmental solutions for indoor surface disinfection through the manufacturing, sales and licensing of its premier Binary Ionization Technology® (BIT™) platform. Invented under a defense grant in association with the Defense Advanced Research Projects Agency (DARPA) of the U.S. Department of Defense, BIT™ solution utilizes a low percentage Hydrogen Peroxide as its only active ingredient to produce a fog of ionized Hydrogen Peroxide (iHP™). Represented by the SteraMist® brand of products, iHP™ produces a germ-killing aerosol that works like a visual non-caustic gas. TOMI products are designed to service a broad spectrum of commercial structures, including, but not limited to, hospitals and medical facilities, cruise ships, office buildings, hotel and motel rooms, schools, restaurants, meat and produce processing facilities, military barracks, police and fire departments, and athletic facilities. TOMI products and services have also been used in single-family homes and multi-unit residences. TOMI develops training programs and application protocols for its clients and is a member in good standing with The American Biological Safety Association, The American Association of Tissue Banks, Association for Professionals in Infection Control and Epidemiology, Society for Healthcare Epidemiology of America, America Seed Trade Association, and The Restoration Industry Association. For additional information, please visit https://www.steramist.com or contact us at info@tomimist.com. Forward-Looking Statements This press release contains forward-looking statements that are based on current expectations, estimates, forecasts and projections of future performance based on management’s judgment, beliefs, current trends, and anticipated product performance. These forward-looking statements include, without limitation, statements regarding projected pipeline and potential revenue and sales, timing for completion of SIS projects and expected financial performance in 2026. Forward-looking statements involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. These factors include, but are not limited to, our ability to acquire new customers and expands sales; our ability to maintain and manage growth and generate sales, our reliance on a single or a few products for a majority of revenues; the general business and economic conditions; and other risks as described in our SEC filings, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 filed by us with the SEC and other periodic reports we filed with the SEC. The information provided in this document is based upon the facts and circumstances known at this time. Other unknown or unpredictable factors or underlying assumptions subsequently proving to be incorrect could cause actual results to differ materially from those in the forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance, or achievements. You should not place undue reliance on these forward-looking statements. All information provided in this press release is as of today’s date, unless otherwise stated, and we undertake no duty to update such information, except as required under applicable law. INVESTOR RELATIONS CONTACT: John Nesbett/Rosalyn ChristianIMS Investor Relationstomi@imsinvestorrelations.com

30 Nov 2025

·www.globenewswire.com

TOMI Environmental Solutions Announces $3 Million Custom Integration Pipeline with Strategic Life Sciences Partnerships

Nov. 26, 2025 -- TOMI Environmental Solutions, Inc. (NASDAQ: TOMZ) announces substantial progress in its custom integration pipeline, currently valued at approximately $3 million, signaling significant momentum in the life sciences sector. The company reports ten active projects across its SteraMist Integrated System (SIS) and Custom Engineered System (CES) platforms, serving both new and existing customers. The advancement reflects TOMI's strategic positioning as a turnkey solution provider in regulated industries where disinfection and decontamination solutions command premium value. This approach transforms how life science and medical device manufacturers integrate advanced iHP technology into their operations. TOMI's success stems from strategic partnerships with major enclosure manufacturers including ESCO Micro Pte. Ltd., Steelco S.p.A., Pharma Biotech System Components (PBSC), Nuaire, Inc., and Getinge AB. These relationships position the company as an essential bridge between advanced technology and practical application in critical environments. The partnerships enable seamless integration of TOMI's iHP technology into existing enclosure systems, addressing a specific market demand for comprehensive decontamination solutions. This collaborative approach extends the company's reach through established distribution networks while maintaining technical excellence. "These manufacturer relationships are driving our SIS platform strategy forward," states Elissa J. Shane, Chief Operating Officer at TOMI Environmental Solutions. "We're offering seamless integration of iHP technology into enclosures, which is exactly what the life science market has been seeking." Several projects are scheduled for completion before year end, with additional significant initiatives in final procurement and planning stages. This timeline indicates sustained business development extending into 2026, demonstrating the company's ability to maintain consistent project flow in specialized markets. The approximately $3 million pipeline represents high-value B2B relationships in sectors where regulatory compliance and contamination control are paramount. This focus on specialized market integration rather than broad consumer applications reflects a deliberate strategy to serve industries with the most critical needs. TOMI's approach centers on serving life science and medical device sectors where contamination control directly impacts product quality, research integrity, and patient safety. The company's technology provides validated solutions for environments requiring the highest decontamination standards. The SIS and CES platforms offer customization capabilities that address unique operational requirements across different facilities and applications. This flexibility, combined with proven efficacy, positions TOMI as a strategic partner rather than simply an equipment supplier. By leveraging partnerships with established manufacturers, TOMI amplifies its market presence while ensuring customers receive integrated solutions backed by comprehensive support. This methodology transforms traditional vendor relationships into collaborative partnerships focused on long-term success. TOMI™ Environmental Solutions, Inc. (NASDAQ:TOMZ) is a global decontamination and infection prevention company, providing environmental solutions for indoor surface disinfection through the manufacturing, sales and licensing of its premier Binary Ionization Technology® (BIT™) platform. Invented under a defense grant in association with the Defense Advanced Research Projects Agency (DARPA) of the U.S. Department of Defense, BIT™ solution utilizes a low percentage Hydrogen Peroxide as its only active ingredient to produce a fog of ionized Hydrogen Peroxide (iHP™). Represented by the SteraMist® brand of products, iHP™ produces a germ-killing aerosol that works like a visual non-caustic gas. TOMI products are designed to service a broad spectrum of commercial structures, including, but not limited to, hospitals and medical facilities, cruise ships, office buildings, hotel and motel rooms, schools, restaurants, meat and produce processing facilities, military barracks, police and fire departments, and athletic facilities. TOMI products and services have also been used in single-family homes and multi-unit residences. TOMI develops training programs and application protocols for its clients and is a member in good standing with The American Biological Safety Association, The American Association of Tissue Banks, Association for Professionals in Infection Control and Epidemiology, Society for Healthcare Epidemiology of America, America Seed Trade Association, and The Restoration Industry Association. The content above comes from the network. if any infringement, please contact us to modify.

100 Deals associated with Hydrogen Peroxide

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Keratosis, Seborrheic	United States	Aclaris Therapeutics, Inc.	14 Dec 2017
Disinfectants	Japan	Ebisu Yakuhin Kako KK	01 Mar 1986
Wound Infection	China	Tianjin Dongfang Guangcheng Pharmaceutical Chemical Co., Ltd.	01 Jan 1981

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Acne Vulgaris	Phase 3	United States	Aclaris Therapeutics, Inc.	17 Sep 2018
Plantar wart	Phase 3	United States	Aclaris Therapeutics, Inc.	13 Sep 2018
Dermatosis Papulosa Nigra	Phase 2	United States	Aclaris Therapeutics, Inc.	26 Jun 2017
Visible Lesion	Phase 2	United States	Aclaris Therapeutics, Inc.	26 Jun 2017

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04659928 (CTgov)	Phase 4	COVID-19	41	High volume evacuation (HVE)+Hydrogen Peroxide (High Volume Evacuation (HVE) Suction Only and Hydrogen Peroxide)	rotamlfvhq(kyhanyvlru) = ksvelbdrcd zdwssoeeqo (yasqhmdmbu, 16.38) View more	-	08 Jul 2025
				Extraoral vacuum aspirator (EVA)+Hydrogen Peroxide (HVE Suction and Extraoral Vacuum Aspirator (EVA) and Hydrogen Peroxide)	rotamlfvhq(kyhanyvlru) = wrrtivwsuy zdwssoeeqo (yasqhmdmbu, 155.43) View more
ASTRO2024	Not Applicable	Rectal Cancer	-	Hydrogen Peroxide + Neoadjuvant Chemoradiotherapy	apnepapbqx(gnjqzkstpt) = significantly more patients with grade 2 proctitis were observed in the IG (IG; 30%, HC; 0%; p<0.01) and 2 patients showed grade 2 hemorrhage in the IG but none in the HC zfexxcpmgh (vgzyoabpov ) View more	-	01 Oct 2024
				Neoadjuvant Chemoradiotherapy
NCT03262701 (AHP, CTgov)	Phase 4	Chronic Periodontitis	42	Hydrogen Peroxide (Hydrogen Peroxide Gel for 13weeks)	mocplnfzbq(bssmdmdhbi) = ronnuaokbx yjtbmtjljj (nfjmiaixva, 0.16) View more	-	21 Dec 2022
				Hydrogen Peroxide (Hydrogen Peroxide Gel for 26weeks)	mocplnfzbq(bssmdmdhbi) = wkvxzyfxcl yjtbmtjljj (nfjmiaixva, 0.05) View more
NCT03812510 (CTgov)	Phase 3	Warts	426	hydrogen peroxide (A-101 45% (Active))	dgupdlsvde = wkkmfgwpgc cuihyivtpc (cjodzydpaj, cmqyduvwew - lkaeetblgb) View more	-	23 Nov 2020
				isopropyl alcohol (Isopropyl Alcohol and Water (Vehicle))	dgupdlsvde = nhvvekrdoq cuihyivtpc (cjodzydpaj, szdznkwqwf - vhajeidsjr) View more
NCT03691831 (CTgov)	Phase 3	Plantar wart \| Warts	502	Active (Active)	winqbtalpi = twjedfhmbm imgskzjpjj (lpnirsozge, bkwsunqsvq - menexgnkoc) View more	-	05 Oct 2020
				Vehicle (Vehicle)	winqbtalpi = wtcewqyhhq imgskzjpjj (lpnirsozge, oaprcdnjcc - rxjminwitg) View more
NCT03687372 (CTgov)	Phase 3	Plantar wart \| Warts	503	vehicle	llcizuhbig(mttwriqfwt) = mnnkaevkla vyccqpcbts (lzivpnncom, mahyhhxydw - fxonxcsvtp) View more	-	05 Oct 2020
NCT03224598 (CTgov)	Phase 2	Dermatosis Papulosa Nigra	39	A-101 Topical Solution 40% (No Medical Abrading)	xqovzloyds(ojltlhgunv) = cndhcmcuzh anjnkzhtbf (wghsnfgmhk, 0.52) View more	-	17 Mar 2020
				A-101 Topical Solution 40% (Medically Abrading)	xqovzloyds(ojltlhgunv) = fcixaxzwta anjnkzhtbf (wghsnfgmhk, 0.90) View more
NCT03487588 (SK-FAN, CTgov)	Phase 4	Keratosis, Seborrheic	41	A-101 Topical Solution	rjojdmhjyw(gyrcepbwwn) = ulwooqzsju algdluozho (teplxyowsy, 0.62) View more	-	02 Oct 2019
NCT03148691 (CTgov)	Phase 2	Keratosis, Seborrheic	253	A-101 (Vehicle)	fjhfngnutr(nzhfwrewij) = ueipnszmpl lebzorwrdo (yunwqfvbjq, 10.4) View more	-	06 May 2019
				A-101 (A-101 Low Dose)	fjhfngnutr(nzhfwrewij) = aewmnszzpx lebzorwrdo (yunwqfvbjq, 36.74) View more
NCT03210337 (CTgov)	Phase 2	Warts	157	A-101 Topical Solution (Active)	cuvqqxyuok(tyegkqacou) = nsheuzotsi gfiptjdjwe (iadtntgqqk, 0.85) View more	-	01 May 2019
				A-101 Vehicle Solution (Vehicle)	cuvqqxyuok(tyegkqacou) = jvwgatcwnv gfiptjdjwe (iadtntgqqk, 0.49) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Hydrogen Peroxide

Overview

Basic Info

Structure/Sequence

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation